Advances in Targeting Homologous Recombination Deficiency for Cancer Therapy: From Clinical Trials to Resistance Mechanisms(2020-2024)
Targeting HRD Cancer: PARP inhibitor clinical trials (BRCA), resistance mechanisms (Polθ) & alternative therapeutic strategies reviewed.